Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of “Quality, Affordable Self-care Products™", today announced that it has settled its Hatch-Waxman litigation relating to its first-to-file Abbreviated New Drug Application for the generic equivalent to Jublia® (efinaconazole) Topical Solution 10% brought by Valeant Pharmaceuticals North America LLC, Valeant Pharmaceuticals Ireland LTD.
February 13, 2019
· 4 min read